More Than 1,700 GranuFlo Cases Filed in Federal Court, Baron and Budd Reports

U.S. Judicial Panel on Multidistrict Litigation Provides Updated Numbers

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend

BOSTON. MA (PRWEB) June 21, 2014

More than 1,700 GranuFlo lawsuits have been filed in a Massachusetts federal court, reports the national law firm of Baron and Budd. The U.S. Judicial Panel on Multidistrict Litigation issued an updated Case List on May 15, 2014 that showed 1,717 complaints have been filed on the behalf of patients who used GranuFlo or NaturaLyte during kidney dialysis treatment and were allegedly injured as a result. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

Manufactured by Fresenius Medical Care, GranuFlo and NaturaLyte are concentrates designed to neutralize acid in the blood of patients suffering from kidney failure. Court documents show that all GranuFlo/NaturaLyte lawsuits allege that the products put patients at a higher risk of suffering several catastrophic cardiovascular problems, including heart attacks and sudden cardiac arrests. On March 29, 2012, the U.S. Food and Drug Administration issued a Class I recall of both GranuFlo and NaturaLyte. (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=109861)

Plaintiffs allege that Fresenius was aware of these problems before issuing a recall in 2012. In 2012, The New York Times reported Fresenius was aware that more than 900 patients being treated with these dialysates in the company’s dialysis centers had suffered cardiac arrest in 2010. The increased risk of cardiac arrest, according to the article, was caused by elevated levels of bicarbonate in the blood. Plaintiffs claim that Fresenius withheld this information from thousands of dialysis clinics outside of the company’s network. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0)

“The fact that so many patients were allegedly harmed by using GranuFlo and NatruaLyte makes us more determined than ever to fight for their rights,” said Laura Baughman, shareholder at Baron and Budd. “The increasing number of lawsuits being filed shows that more and more people’s lives have been forever altered after using products they trusted to treat their kidney problems.”

If someone you know has suffered a cardiac arrest or heart attack during or shortly after dialysis treatment, the national law firm of Baron and Budd is ready to help. Call 866-472-9108 or visit our website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/ to learn more regarding how we may be of assistance.

ABOUT BARON & BUDD, P.C.
The attorneys at Baron and Budd have been Protecting What’s Right for consumers for more than 35 years. Over the years, our national law firm has built a successful track record representing people who have been harmed by corporate wrongdoing. The firm’s pharmaceutical lawyers recently represented over 7,000 patients harmed by using the drug Avandia. Previously, Baron & Budd played a prominent role in litigation related to the diet drug Fen-Phen. As a result, the case settled for an amount valued at more than $1.275 billion (In Re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.).


Contact